Factors determining altered perfusion after acute pulmonary embolism assessed by quantified single-photon emission computed tomography-perfusion scan

Marc Meysman, Hendrik Everaert, Walter Vincken, Marc Meysman, Hendrik Everaert, Walter Vincken

Abstract

Aim of the study: The aim of the study was to analyze the evolution of perfusion (Q)-defects in patients treated for acute pulmonary embolism (PE), correlation with baseline parameters and evaluation of recurrence risk.

Methods: This is a single-center prospective observational cohort study in symptomatic normotensive PE. Comparison of the ventilation/perfusion single-photon emission computed tomography (V/Q-SPECT) acquired at baseline with a quantified SPECT (Q-SPECT) repeated at 1 week and 6 months. The Q-defect extent (percentage of total lung volume affected) was measured semiquantitatively. Data collected at baseline were age, gender, body mass index (BMI), history of previous venous thromboembolism (HVTE), Charlson's Comorbidity Score (CcS), plasma troponin-T and D-dimer levels, PE Severity Index, and tricuspid regurgitation jet (TRJ) velocity.

Results: Forty-six patients (22 men/24 women, mean age 61.7 years (± standard deviation 16.3)) completed the study. At 1 week, 13/46 (28.3 %) and at 6 months 22/46 (47.8%) patients had completely normalized Q-SPECT. Persistence of Q-defects was more frequent in female patients in univariate and multivariate analysis. We found no correlation between the persistence of Q-defects on Q-SPECT and HVTE, BMI, plasma troponin-T, and CcS. However, lower TRJ and younger age were statistically significantly linked to normalization of Q-scans after 6 months of treatment only in univariate analysis. There is no difference in the frequency of recurrent PE in relation to the persistence of Q-defects.

Conclusion: Acute PE patients of female, older age, and higher TRJ in univariate analysis and patients of female in multivariate analysis seem to have a higher risk of persistent Q-defects after 6 months treatment. The presence of residual Q-abnormalities at 6 months was not associated with an increased risk for recurrent PE.

Keywords: Pulmonary embolism; recurrent pulmonary embolism; residual perfusion defects.

Conflict of interest statement

There are no conflicts of interest.

References

    1. Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO. American College of Chest Physicians. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e691S–736S.
    1. van Es J, Douma RA, Gerdes VE, Kamphuisen PW, Büller HR. Acute pulmonary embolism. Part 2: Treatment. Nat Rev Cardiol. 2010;7:613–22.
    1. Bajc M, Neilly JB, Miniati M, Schuemichen C, Meignan M, Jonson B. EANM guidelines for ventilation/perfusion scintigraphy: Part 2.Algorithms and clinical considerations for diagnosis of pulmonary emboli with V/P (SPECT) and MDCT. Eur J Nucl Med Mol Imaging. 2009;36:1528–38.
    1. Torbicki A, Perrier A, Konstantinides S, Agnelli G, Galiè N, Pruszczyk P, et al. Guidelines on the diagnosis and management of acute pulmonary embolism: The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC) Eur Heart J. 2008;29:2276–315.
    1. Hall WH, Ramachandran R, Narayan S, Jani AB, Vijayakumar S. An electronic application for rapidly calculating Charlson comorbidity score. BMC Cancer. 2004;4:94.
    1. Aujesky D, Roy PM, Le Manach CP, Verschuren F, Meyer G, Obrosky DS, et al. Validation of a model to predict adverse outcomes in patients with pulmonary embolism. Eur Heart J. 2006;27:476–81.
    1. Chan CM, Woods C, Shorr AF. The validation and reproducibility of the pulmonary embolism severity index. J Thromb Haemost. 2010;8:1509–14.
    1. Zhu T, Martinez I, Emmerich J. Venous thromboembolism: Risk factors for recurrence. Arterioscler Thromb Vasc Biol. 2009;29:298–310.
    1. Nijkeuter M, Hovens MM, Davidson BL, Huisman MV. Resolution of thromboemboli in patients with acute pulmonary embolism: A systematic review. Chest. 2006;129:192–7.
    1. Miniati M, Monti S, Bottai M, Scoscia E, Bauleo C, Tonelli L, et al. Survival and restoration of pulmonary perfusion in a long-term follow-up of patients after acute pulmonary embolism. Medicine (Baltimore) 2006;85:253–62.
    1. Sanchez O, Helley D, Couchon S, Roux A, Delaval A, Trinquart L, et al. Perfusion defects after pulmonary embolism: Risk factors and clinical significance. J Thromb Haemost. 2010;8:1248–55.
    1. Stein PD, Yaekoub AY, Matta F, Janjua M, Patel RM, Goodman LR, et al. Resolution of pulmonary embolism on CT pulmonary angiography. AJR Am J Roentgenol. 2010;194:1263–8.
    1. Cosmi B, Nijkeuter M, Valentino M, Huisman MV, Barozzi L, Palareti G. Residual emboli on lung perfusion scan or multidetector computed tomography after a first episode of acute pulmonary embolism. Intern Emerg Med. 2011;6:521–8.
    1. Alonso-Martínez JL, Anniccherico-Sánchez FJ, Urbieta-Echezarreta MA, García-Sanchotena JL, Herrero HG. Residual pulmonary thromboemboli after acute pulmonary embolism. Eur J Intern Med. 2012;23:379–83.
    1. den Exter PL, van Es J, Kroft LJ, Erkens PM, Douma RA, Mos IC, et al. Thromboembolic resolution assessed by CT pulmonary angiography after treatment for acute pulmonary embolism. Thromb Haemost. 2015;114:26–34.
    1. Pesavento R, Filippi L, Pagnan A, Visonà A, Pauletto P, Vescovo G, et al. Unexpectedly high recanalization rate in patients with pulmonary embolism treated with anticoagulants alone. Am J Respir Crit Care Med. 2014;189:1277–9.
    1. Hvid-Jacobsen K, Fogh J, Nielsen SL, Thomsen HS, Hartling OJ. Scintigraphic control of pulmonary embolism. Eur J Nucl Med. 1988;14:71–2.
    1. Wartski M, Collignon MA. Incomplete recovery of lung perfusion after 3 months in patients with acute pulmonary embolism treated with antithrombotic agents. THESEE Study Group. Tinzaparin ou Heparin Standard: Evaluation dans l'Embolie Pulmonaire Study. J Nucl Med. 2000;41:1043–8.
    1. Donadini MP, Dentali F, Cosmi B, Bozzato S, Neri C, Squizzato A, et al. Presence of residual thromboemboli at least six months after a first episode of symptomatic pulmonary embolism: Do perfusion scintigraphy and angio-computed tomography agree? Thromb Haemost. 2009;102:1287–9.
    1. Leblanc M, Paul N. V/Q SPECT and computed tomographic pulmonary angiography. Semin Nucl Med. 2010;40:426–41.
    1. Begic A, Jögi J, Hadziredzepovic A, Kucukalic-Selimovic E, Begovic-Hadzimuratovic S, Bajc M. Tomographic ventilation/perfusion lung scintigraphy in the monitoring of the effect of treatment in pulmonary embolism: Serial follow-up over a 6-month period. Nucl Med Commun. 2011;32:508–14.
    1. Meysman M, Everaert H, Buls N, Nieboer K, de Mey J. Comparison of ventilation-perfusion single-photon emission computed tomography (V/Q SPECT) versus dual-energy CT perfusion and angiography (DECT) after 6 months of pulmonary embolism (PE) treatment. Eur J Radiol. 2015;84:1816–9.
    1. Klok FA, Mos IC, Huisman MV. Brain-type natriuretic peptide levels in the prediction of adverse outcome in patients with pulmonary embolism: A systematic review and meta-analysis. Am J Respir Crit Care Med. 2008;178:425–30.
    1. Tan M, Mos IC, Klok FA, Huisman MV. Residual venous thrombosis as predictive factor for recurrent venous thromboembolim in patients with proximal deep vein thrombosis: A sytematic review. Br J Haematol. 2011;153:168–78.
    1. Alhadad A, Miniati M, Alhadad H, Gottsäter A, Bajc M. The value of tomographic ventilation/perfusion scintigraphy (V/PSPECT) for follow-up and prediction of recurrence in pulmonary embolism. Thromb Res. 2012;130:877–81.
    1. Poli D, Cenci C, Antonucci E, Grifoni E, Arcangeli C, Prisco D, et al. Risk of recurrence in patients with pulmonary embolism: Predictive role of D-dimer and of residual perfusion defects on lung scintigraphy. Thromb Haemost. 2013;109:181–6.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel